Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Letter to the Editor

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw

Authors: Bruno Vincenzi, Andrea Napolitano, Alice Zoccoli, Michele Iuliani, Francesco Pantano, Nicola Papapietro, Vincenzo Denaro, Daniele Santini, Giuseppe Tonini

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

Recent studies have been reported that angiogenesis suppression may play a role in developing bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of VEGF as predictive marker of B-ONJ onset. Of the 81 patients, 6 developed B-ONJ following bisphosphonate treatment. These patients showed a strongest decrease in VEGF circulating levels at day 7 and at day 21 after the first administration. These data demonstrated for the first time that the anti-angiogenic properties of bisphosphonates are directly linked to B-ONJ pathogenesis and serum VEGF levels could represent an effective early predictive marker.
Literature
1.
Reid IR, Cornish J: Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2011, 8: 90-96.PubMed
2.
Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, Huryn JM: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008, 26: 4037-4038. 10.1200/JCO.2007.15.5424.CrossRefPubMed
3.
Greuter S, Schmid F, Ruhstaller T, Thuerlimann B: Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008, 19: 2091-2092. 10.1093/annonc/mdn653.PubMedCentralCrossRefPubMed
4.
Yin G, Bai Y, Luo E: Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw. Med Hypotheses. 2011, 76: 347-349. 10.1016/j.mehy.2010.10.036.CrossRefPubMed
5.
Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003, 9: 2893-2897.PubMed
6.
Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G: Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002, 8: 1080-1084.PubMed
7.
Santini D, Vincenzi B, Tonini G, Scarpa S, Baldi A: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003, 9: 3215-author reply 3216PubMed
Metadata
Title
Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
Authors
Bruno Vincenzi
Andrea Napolitano
Alice Zoccoli
Michele Iuliani
Francesco Pantano
Nicola Papapietro
Vincenzo Denaro
Daniele Santini
Giuseppe Tonini
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-56

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue

Research

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

Rapid communication

Homozygous A polymorphism of the complement C1qA 276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP

Research

Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness

Research

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Rapid communication

Novel human polyomaviruses, Merkel cell polyomavirus and human polyomavirus 9, in Japanese chronic lymphocytic leukemia cases

Research

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits